Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells

British Journal of Cancer

Volumn 106, Issue 8, 2012, Pages 1395-1405

  Stein, U ^a   Fleuter, C ^a   Siegel, F ^a   Smith, J ^a   Kopacek, A ^a   Scudiero, D A ^b   Hite, K M ^b   Schlag, P M ^c   Shoemaker, R H ^d   Walther, W ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b SAIC FREDERICK INC   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

catenin; ABCB1; colon cancer; multidrug resistance; therapy response

Indexed keywords

ALVESPIMYCIN; AZACITIDINE; BELINOSTAT; BETA CATENIN; BORTEZOMIB; CYCLOPAMINE; DASATINIB; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; MELPHALAN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; MUTANT PROTEIN; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PACLITAXEL; SMALL INTERFERING RNA; SORAFENIB; SULINDAC; SUNITINIB; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN HCT116; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLON CANCER; FEMALE; GAIN OF FUNCTION MUTATION; GENETIC TRANSFECTION; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SAMPLE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MUTANT PROTEINS; P-GLYCOPROTEIN; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84859637291     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.81     Document Type: Article

References (52)

1. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, Wang S, Weinstein IB, Holt PR (1996) Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110: 669-674 (Pubitemid 26071834)
2. Bienz M, Clevers H (2000) Linking colorectal cancer to Wnt signaling. Cell 103: 311-320
3. Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R, Pals ST (2004) Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 90: 224-229 (Pubitemid 38174965)
4. Bourguignon LY, Xia W, Wong G (2009) Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J Biol Chem 284: 2657-2671
5. Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW (2002) Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci USA 99: 8265-8270 (Pubitemid 34651041)
6. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, Katano M (2010) Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 30: 2041-2048
7. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287 (Pubitemid 20266126)
8. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767
9. Gardner SH, Hawcroft G, Hull MA (2004) Effect of nonsteroidal antiinflammatory drugs on beta-catenin protein levels and cateninrelated transcription in human colorectal cancer cells. Br J Cancer 91: 153-163 (Pubitemid 39013060)
10. Gillet JP, Gottesman MM (2011) Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol 12: 686-692
11. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev 2: 48-58 (Pubitemid 37328807)
12. Han A, Song Z, Tong C, Hu D, Bi X, Augenlicht LH, Yang W (2008) Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol 583: 26-31
13. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512 (Pubitemid 28425575)
14. Ho GT, Moodie FM, Satsangi J (2003) Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52: 759-766 (Pubitemid 36528884)
15. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF (1997) Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 94: 10330-10334 (Pubitemid 27407041)
16. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, Scheper RJ (1996) Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 65: 230-237 (Pubitemid 26051685)
17. Kim IJ, Kang HC, Park JH, Shin Y, Ku JL, Lim SB, Park SY, Jung SY, Kim HK, Park JG (2003) Development and applications of a beta-catenin oligonucleotide microarray: beta-catenin mutations are dominantly found in the proximal colon cancers with microsatellite instability. Clin Cancer Res 9: 2920-2925 (Pubitemid 36993250)
18. Kim JS, Crooks H, Dracheva T, Nishanian TG, Singh B, Jen J, Waldman T (2002) Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res 62: 2744-2748 (Pubitemid 34525754)
19. Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387-398 (Pubitemid 351589714)
20. Kohno K, Sato S, Uchiumi T, Takano H, Kato S, Kuwano M (1990) Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene. J Biol Chem 265: 19690-19696 (Pubitemid 120013917)
21. Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959 (Pubitemid 32652819)
22. Liu YY, Gupta V, Patwardhan GA, Bhinge K, Zhao Y, Bao J, Mehendale H, Cabot MC, Li YT, Jazwinski SM (2010) Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer 9: 145
23. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787-1790 (Pubitemid 27136715)
24. Najdi R, Holcombe RF, Waterman ML (2011) Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog 10: 5
25. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW (1997) Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 272: 24735-24738 (Pubitemid 27415637)
26. Ougolkov AV, Yamashita K, Mai M, Minamoto T (2002) Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 122: 60-71 (Pubitemid 34049195)
27. Polakis P (1999) The oncogenic activation of beta-catenin. Curr Opin Genet Dev 9: 15-21
28. Polakis P (2000) Wnt signaling and cancer. Genes Dev 14: 1837-1851
29. Provost E, Yamamoto Y, Lizardi I, Stern J, D'Aquila TG, Gaynor RB, Rimm DL (2003) Functional correlates of mutations in beta-catenin exon 3 phosphorylation sites. J Biol Chem 278: 31781-31789 (Pubitemid 37048359)
30. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, Ahnen DJ (2003) Sulindac metabolites induce caspase-and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2: 885-892
31. Riordan JR, Ling V (1979) Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 254: 12701-12705 (Pubitemid 10137661)
32. Shekhar MP, Biernat LA, Pernick N, Tait L, Abrams J, Visscher DW (2010) Utility of DNA postreplication repair protein Rad6B in neoadjuvant chemotherapy response. Med Oncol 27: 466-473
33. Stein U, Arlt F, Smith J, Sack U, Herrmann P, Walther W, Lemm M, Fichtner I, Shoemaker RH, Schlag PM (2011) Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia 13: 131-144
34. Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, Schlag PM, Shoemaker RH (2006) The metastasis-associated gene S100A4 is a novel target of betacatenin/T-cell factor signaling in colon cancer. Gastroenterology 131: 1486-1500 (Pubitemid 44708942)
35. Stein U, Jürchott K, Schläfke M, Hohenberger P (2002) Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients. J Clin Oncol 20: 3282-3292 (Pubitemid 34831527)
36. Stein U, Walther W (2006) Current opinion: reversal of ABC transporter-mediated multidrug resistance in cancer: a realistic option? Am J Cancer 5: 285-297 (Pubitemid 46224861)
37. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM (2009) MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15: 59-67
38. Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH (1997a) Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP. J Natl Cancer Inst 89: 807-813 (Pubitemid 27242283)
39. Stein U, Walther W, Lemm M, Naundorf H, Fichtner I (1997b) Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo. Int J Cancer 72: 885-891 (Pubitemid 27431535)
40. Stein U, Walther W, Shoemaker RH (1996) Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 88: 1383-1392 (Pubitemid 26329756)
41. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234 (Pubitemid 43336035)
42. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738
43. Tiwari AK, Sodani K, Dai CL, Ashby Jr CR, Chen ZS (2011) Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12: 570-594
44. Tusnady GE, Sarkadi B, Simon I, Varadi A (2006) Membrane topology of human ABC proteins. FEBS Lett 580: 1017-1022 (Pubitemid 43185282)
45. Ueda K, Cardarelli C, Gottesman MM, Pastan I (1987) Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84: 3004-3008 (Pubitemid 17064766)
46. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250 (Pubitemid 35292444)
47. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799 (Pubitemid 39070849)
48. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB, Coon JS (1991) Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726
49. Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WL (2004) Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 10: 1401-1408 (Pubitemid 38365235)
50. Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR, Shoemaker RH (1992) Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 52: 3029-3034
51. Yamada T, Mori Y, Hayashi R, Takada M, Ino Y, Naishiro Y, Kondo T, Hirohashi S (2003) Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. Cancer Res 63: 895-901 (Pubitemid 36278415)
52. Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, Hirohashi S (2000) Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 60: 4761-4766